Analyst Price Targets — KROS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 11:13 am | Benjamin Burnett | Wells Fargo | $18.00 | $10.11 | TheFly | Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo |
| August 4, 2026 10:53 am | Andrew Fein | H.C. Wainwright | $20.00 | $10.11 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Keros Therapeutics (KROS) |
| August 4, 2026 10:01 am | — | Leerink Partners | $23.00 | $10.11 | TheFly | Keros Therapeutics price target lowered to $23 from $30 at Leerink |
| November 5, 2024 6:47 pm | Kelly Shi | Jefferies | $107.00 | $62.02 | StreetInsider | Jefferies Starts Keros Therapeutics (KROS) at Buy |
| November 5, 2024 11:06 am | Srikripa Devarakonda | Truist Financial | $100.00 | $62.02 | StreetInsider | Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS) |
| September 23, 2024 2:57 am | Vamil Divan | Guggenheim | $96.00 | $55.80 | StreetInsider | Guggenheim Starts Keros Therapeutics (KROS) at Buy |
| June 18, 2024 7:57 am | Joseph Catanzaro | Piper Sandler | $105.00 | $44.65 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS) |
| December 13, 2022 8:49 am | — | BTIG | $105.00 | $49.98 | Benzinga | BTIG Maintains Buy on Keros Therapeutics, Raises Price Target to $105 |
| July 27, 2022 7:59 pm | Julian Harrison | BTIG | $80.00 | $31.79 | Pulse 2.0 | Keros Therapeutics (KROS) Stock: Why It Surged 11.43% Today |
| May 18, 2022 10:06 am | Joseph Catanzaro | Piper Sandler | $120.00 | $39.92 | TheFly | Keros Therapeutics price target raised to $120 from $90 at Piper Sandler |
Latest News for KROS
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
Hsbc Holdings PLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ: KROS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 69,926 shares of the company's stock, valued at approximately $761,000. Hsbc Holdings PLC owned about 0.35% of Keros Therapeutics as
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 453.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,360 shares of the company's stock after buying an additional 263,347 shares during
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KROS.
U.S. House Trading
No House trades found for KROS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.